Update June 12, 2020 – I reached out to both USADA and to the UFC’s Jeff Novitzky and asked them to share any studies or other data they have that can speak to PED’s being transmitted through sexual contact. They shared the following articles:
Potential Seminal Transport of Pharmaceuticals to the Conceptus
The Transport of Chemicals in Semen
Today the United States Anti Doping Agency (“USADA”) published a press release finding a boxer was ‘not at fault’ for prohibited metabolites in her system after finding they “were consistent with recent exposure to the substances via sexual transmission”.
Boxer Virginia Fuchs tested positive for the letrozole metabolite bis-(4-cyanophenyl)methanol, as well as GW1516 (GW501516) metabolites, GW1516 sulfone and GW1516 sulfoxide, as the result of an out-of-competition urine sample she provided on February 13, 2020.
USADA determined that “Fuchs’ male partner was using therapeutic doses of letrozole and GW1516 and the low amounts of letrozole metabolite and GW1516 metabolites detected in her sample were consistent with recent exposure to the substances via sexual transmission”
USADA concluded that this constituted ingestion “without fault or negligence” and as a result “Fuchs will not face a period of ineligibility for her positive test.”
The full press release reads as follows:
USADA announced today that Virginia Fuchs, of Kemah, Texas, an athlete in the sport of boxing, has tested positive for a prohibited substance, which was determined to have been ingested by her without fault or negligence. As a result, Fuchs will not face a period of ineligibility for her positive test.
“While the World Anti-Doping Code requires that this no fault finding be considered a violation and be publicly announced, we strongly believe this case and others like it, including meat contamination and prescription medication contamination cases, should be considered no violation,” said Travis T. Tygart, Chief Executive Officer of USADA. “We will continue to advocate for changes to the World Anti-Doping Code so that where there is no intent to cheat and no performance benefit, an athlete should not face any violation or unnecessary public attention.”
Fuchs, 32, tested positive for the letrozole metabolite bis-(4-cyanophenyl)methanol, as well as GW1516 (GW501516) metabolites, GW1516 sulfone and GW1516 sulfoxide, as the result of an out-of-competition urine sample she provided on February 13, 2020. Letrozole is a Specific Substance and GW1516 is a non-Specified Substance in the class of Hormone and Metabolic Modulators and are prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic & Paralympic Committee National Anti-Doping Policies, and the Association Internationale de Boxe Amateur Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency (WADA) Prohibited List.
During a thorough investigation into the circumstances of Fuchs’ case, USADA determined that Fuchs’ male partner was using therapeutic doses of letrozole and GW1516 and the low amounts of letrozole metabolite and GW1516 metabolites detected in her sample were consistent with recent exposure to the substances via sexual transmission. Additionally, a WADA-accredited laboratory confirmed that products possessed by Fuchs’ partner contained therapeutic amounts of letrozole and GW1516.
Fuchs will not face a period of ineligibility for her positive test, and because the sample was collected out-of-competition, there are no competitive results to disqualify.
In an effort to aid athletes, as well as support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements, as well as performance-enhancing and recreational drugs.
In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and distributes a multitude of educational materials, such as an easy-reference wallet card with examples of prohibited and permitted substances, a supplement guide, a nutrition guide, an athlete handbook, and periodic alerts and advisories.
Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at firstname.lastname@example.org, by phone at 1-877-Play Clean (1-877-752-9253) or by mail.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs